Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Deep Learning Model Based on Contrast-enhanced Ultrasound to Aid Clinical Decisions and Predict Biological Biomarker and Prognosis of Hepatocellular Carcinoma

NCT05257694 is registered in ClinicalTrials.gov with Ping Liang as lead sponsor.

NCT NCT05257694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05257694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Deep Learning Model Based on Contrast-enhanced Ultrasound to Aid Clinical Decisions and Predict Biological Biomarker and Prognosis of Hepatocellular Carcinoma
Lead sponsor
Ping Liang
Phase
Observational
Overall status
Unknown status
Start date
January 1, 2022
Completion date
December 31, 2025
Enrollment
1 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ablation, contrast-enhanced ultrasound, hepatocellular carcinoma, prognosis, surgery